Effectiveness of Atomoxetine and Quality of Life in Children with Attention-Deficit/Hyperactivity Disorder as Perceived by Patients, Parents, and Physicians in an Open-Label Study
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Health-related quality of life in children with attention-deficit/hyperactivity disorder (ADHD) may improve with atomoxetine treatment. However, the degree of improvement may be perceived differently by patients, parents, and physicians. The primary aim of this study was to investigate ADHD-related difficulties as perceived from these three perspectives and to compare the perspectives. The degree of perceived difficulties was taken to reflect the health-related quality of life of patients in the study. A second objective was to assess the effectiveness of atomoxetine in children with ADHD in an open-label setting. METHODS: Children aged 6-11 years with ADHD were treated for 24 weeks with atomoxetine at a target dose of 0.5-1.2 mg/kg per day. ADHD-related difficulties were assessed after 8 and 24 weeks of treatment using the newly devised Global Impression of Perceived Difficulties (GIPD) scale. This instrument, that has not yet been psychometrically validated, reflects patient quality of life from the three perspectives. Agreement among the perspectives was determined using Cohen's kappa. RESULTS: A total of 262 patients was treated with atomoxetine. The mean dose for the respective visit intervals ranged between 1.15 and 1.17 mg/kg per day. Quality of life as reflected by the degree of perceived difficulties improved over time. Change in GIPD scores was greatest within the first 2 weeks. The course of the mean GIPD total scores over time showed a similar pattern among the three different rater perspectives. However, patients perceived the degree of difficulties as significantly less compared to parents and physicians. Agreement of ratings was highest between physicians and parents. CONCLUSIONS: Results from the GIPD suggest that patient quality of life improves with time on atomoxetine. The effectiveness of atomoxetine in an open-label study was very similar to the effectiveness shown in placebo-controlled trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 2×
“…option for ADHD (Banaschewski et al. 2004; Becker et al. 2006), for which efficacy and tolerability in children and adolescents has been demonstrated in a number of randomized, placebo-controlled trials (Michelson et al. 2001; Michelson et al. 2002, Spencer et al. 2002; Kelsey et al. 2004).”
Klassen, A. F., Miller, A., & Fine, S. (2004) · Pediatrics · doi:10.1542/peds.2004-0844 · Cited by 565 · cited 2×
“…with significant impairment of cognitive and psychosocial functioning (Barkley 2002; Biederman and Faraone 2005) and quality of life in patients and their families (Johnston and Mash 2001; Sawyer et al. 2002; Klassen et al. 2004; Matza et al. 2004; Escobar et al. 2005; Riley et al. 2006).”
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464
Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · cited 6×
“The AEs reported in this study were very similar to those reported in randomized, placebo-controlled trials (Michelson et al. 2001; Spencer et al. 2002; Biederman et al. 2002; Kelsey et al. 2004).”
InfluentialNewcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200503000-00008 · Cited by 174 · cited 1×
“This finding was expected, because atomoxetine is known to improve both hyperactive/impulsive and inat-tentive symptoms of ADHD (Michelson et al. 2001; Spencer et al. 2002; Kelsey et al. 2004; Newcorn et al. 2005).”
Riley, A. W., Spiel, G., Coghill, D., Döpfner, M., Falissard, B., Lorenzo, M. J., Preuss, U., Ralston**, S. J., & ADORE Study Group* (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-1006-9 · Cited by 156
MATZA, L. S., RENTZ, A. M., SECNIK, K., SWENSEN, A. R., REVICKI, D. A., MICHELSON, D., SPENCER, T., NEWCORN, J. H., & KRATOCHVIL, C. J. (2004) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200406000-00005 · Cited by 119 · cited 1×
“…with significant impairment of cognitive and psychosocial functioning (Barkley 2002; Biederman and Faraone 2005) and quality of life in patients and their families (Johnston and Mash 2001; Sawyer et al. 2002; Klassen et al. 2004; Matza et al. 2004; Escobar et al. 2005; Riley et al. 2006).”
Prasad, S., Harpin, V., Poole, L., Zeitlin, H., Jamdar, S., Puvanendran, K., & on behalf of the SUNBEAM Study Group (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167309 · Cited by 97 · cited 3×
“In addition, several studies have shown improvement of health-related quality of life in children and adolescents treated with atomoxetine (Michelson et al. 2001; Buitelaar et al. 2004; Perwien et al. 2004; Brown et al. 2006; Matza et al. 2006; Perwien et al. 2006; Prasad et al. 2007).”
InfluentialPerwien, A. R., Kratochvil, C. J., Faries, D. E., Vaughan, B. S., Spencer, T., & Brown, R. T. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.713 · Cited by 74 · cited 4×
“In addition, several studies have shown improvement of health-related quality of life in children and adolescents treated with atomoxetine (Michelson et al. 2001; Buitelaar et al. 2004; Perwien et al. 2004; Brown et al. 2006; Matza et al. 2006; Perwien et al. 2006; Prasad et al. 2007).”
Influential
Cited by
Wehmeier, P. M., Schacht, A., & Barkley, R. A. (2010) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2009.09.009 · Cited by 628
Self-citationThe quality of life of children with attention deficit/hyperactivity disorder: a systematic review
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., Santosh, P., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0046-3 · Cited by 516
“[ 88 ] Open label trial (ATX) GIPD Child, parent, physician 262 ADHD 24 weeks It is questionable whether the GIPD is a true measure of”
BackgroundReed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“Functional outcomes/quality of life 36 [14, 18, 57, 71, 72, 76, 77, 87, 89, 94, 100–125]”
BackgroundMethodPerwien, A. R., Kratochvil, C. J., Faries, D. E., Vaughan, B. S., Spencer, T., & Brown, R. T. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.713 · Cited by 74
Self-Esteem Evaluation in Children and Adolescents Suffering from ADHD
Mazzone, L., Postorino, V., Reale, L., Guarnera, M., Mannino, V., Armando, M., Fatta, L., De Peppo, L., & Vicari, S. (2013) · Clinical Practice & Epidemiology in Mental Health · doi:10.2174/1745017901309010096 · Cited by 62
“[35] Peter M, Wehmeier AS, Dittmann RW, et al.”
Background
Metadata
- Authors
- Wehmeier, P. M., Dittmann, R. W., Schacht, A., Minarzyk, A., Lehmann, M., Sevecke, K., & Lehmkuhl, G.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2007-12
- Volume
- 17
- Issue
- 6
- Pages
- 813-830
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2011056969
- Cited by
- 30
- References
- 10
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of Atomoxetine and Quality of Life in Children with Attention-Deficit/Hyperactivity Disorder as Perceived by Patients, Parents, and Physicians in an Open-Label Study. https://app.cochat.ai/papers/10.1089/cap.2007.0025
- The paper
- Wehmeier, P. M., Dittmann, R. W., Schacht, A., Minarzyk, A., Lehmann, M., Sevecke, K., & Lehmkuhl, G. (2007). Effectiveness of Atomoxetine and Quality of Life in Children with Attention-Deficit/Hyperactivity Disorder as Perceived by Patients, Parents, and Physicians in an Open-Label Study. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2007.0025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.